A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Public ClinicalTrials.gov record NCT06843447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Study identification
- NCT ID
- NCT06843447
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 605 participants
Conditions and interventions
Conditions
Interventions
- Raludotatug Deruxtecan Biological
- Carboplatin Drug
- Paclitaxel Drug
- Bevacizumab Biological
- Rescue Medication Drug
- Pembrolizumab Biological
- Gemcitabine Drug
- Pegylated liposomal doxorubicin Drug
- MK-2010 Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2025
- Primary completion
- Mar 26, 2029
- Completion
- Feb 6, 2031
- Last update posted
- Sep 1, 2026
2025 – 2031
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) | New Haven | Connecticut | 06510 | Recruiting |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0009) | Louisville | Kentucky | 40202 | Recruiting |
| TRIALS 365 ( Site 0020) | Shreveport | Louisiana | 71103 | Recruiting |
| Dana-Farber Cancer Institute ( Site 0015) | Boston | Massachusetts | 02215 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0003) | New York | New York | 10065 | Recruiting |
| OU Health University of Oklahoma Medical Center ( Site 7000) | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Texas Oncology - DFW ( Site 8000) | Fort Worth | Texas | 76104 | Recruiting |
| Houston Methodist Hospital ( Site 0010) | Houston | Texas | 77030 | Completed |
| START Mountain Region ( Site 0008) | West Valley City | Utah | 84119 | Recruiting |
| University of Virginia Health System ( Site 0011) | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06843447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06843447 live on ClinicalTrials.gov.